Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology

References

• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101-10
   PubMed Web of Science ®Google Scholar
• Goede V, Engelke A, Fischer K, et al. Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities: results of the CLL11 Study [abstract 3327]. American Society of Hematology (ASH) Annual Meeting; 6–9 December 2014; San Francisco, CA
   Google Scholar
• Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008;112(1):119-28
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Villamor N, Terol MJ, et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood 2013;122(24):3951-9
   PubMed Web of Science ®Google Scholar
• Greil R, Obrtlikova P, Smolej L, et al. Rituximab maintenance after chemoimmunotherapy induction in 1st and 2nd line improves progression free survival: planned interim analysis of the international randomized AGMT-CLL8/a Mabtenance trial [abstract 20]. American Society of Hematology (ASH) Annual Meeting; 6–9 December 2014; San Francisco, CA
   Google Scholar
• van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: prolong study interim analysis result [abstract 21]. American Society of Hematology (ASH) Annual Meeting; December 6-9, 2014; San Francisco, CA
   Google Scholar
• Eichhorst B, Bahlo J, Fink AM, et al. Good tolerance of lenalidomide maintenance therapy in patients with high risk profile chronic lymphocytic leukemia (CLL) after frontline chemoimmunotherapy: preliminary safety overview of the CLLM1 trial of the German CLL study group (GCLLSG) [abstract 4699]. American Society of Hematology (ASH) Annual Meeting; 6-9 December 2014; San Francisco, CA
   Google Scholar
• Robak T. Maintenance in CLL. Blood 2013;122(24):3854-5
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) shows superior efficacy in comparison to bendamustine and rituximab (BR) in previously untreated and physically fit patients with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study) [abstract 19]. American Society of Hematology (ASH) Annual Meeting; 6-9 December 2014; San Francisco, CA
   Google Scholar
• Cuneo A, Marchetti M, Barosi G, et al. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leuk Res 2014;38(11):1269-77
   PubMed Web of Science ®Google Scholar
• Kovacs G, Boettcher S, Bahlo J, et al. Value of minimal residual disease (MRD) negative status at response evaluation in chronic lymphocytic leukemia (CLL): combined analysis of two phase III studies of the German CLL study group (GCLLSG) [abstract 23]. American Society of Hematology (ASH) Annual Meeting. 6–9 December 2014; San Francisco, CA
   Google Scholar
• Brown JR, Hillmen P, O’Brien S, et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE™ trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract 3331]. American Society of Hematology (ASH) Annual Meeting. 6–9 December 2014; San Francisco, CA
   Google Scholar
• Barrientos JC, O’Brien S, Brown JR, et al. Hematologic and immunologic function and patient well-being for the phase III RESONATE™ study of ibrutinib vs ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract 4696]. American Society of Hematology (ASH) Annual Meeting. 6–9 December 2014; San Francisco, CA
   Google Scholar
• O’Brien S, Jones JA, Coutre S, et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial [abstract 327]. American Society of Hematology (ASH) Annual Meeting. 6–9 December 2014; San Francisco, CA
   Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371(3):213-23
   PubMed Web of Science ®Google Scholar
• Tam CS, Stilgenbauer S. Clinical dilemmas: how best to manage CLL patients with 17p Deletion and/or TP53 mutation? Leuk Lymphoma 2015;56(3):587-93
   PubMed Web of Science ®Google Scholar
• Thompsonm PA, Wierda WG, Ferrajoli A, et al. Complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens [abstract 22]. American Society of Hematology (ASH) Annual Meeting; 6–9 December 2014; San Francisco, CA
   Google Scholar
• Fegan C, Bagshawe J, Salles G, et al. The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: promising single agent activity and well tolerated in patients with high risk chronic lymphocytic leukaemia (CLL) [abstract 3328]. American Society of Hematology (ASH) Annual Meeting; 6–9 December 2014; San Francisco, CA
   Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370:997-1007
   PubMed Web of Science ®Google Scholar
• Coutre SE, Furman RR, Sharman JP, et al. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. J Clin Oncol 2014;32:5s (Suppl; abstr 7012)
   Google Scholar
• Sharman JP, Coutre SE, Furman RR, et al. Second interim analysis of a phase 3 study of idelalisib (Zydelig®) plus rituximab for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract 330]. American Society of Hematology (ASH) Annual Meeting; 6–9 December 2014; San Francisco, CA
   Google Scholar
• Zelenetz AD, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract 1986]. AmericanSociety of Hematology (ASH) Annual Meeting; 6–9 December 2014; San Francisco, CA
   Google Scholar
• O’Brien S, Patel M, Kahl BS, et al. Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia [abstract 3334]. AmericanSociety of Hematology (ASH) Annual Meeting. 6–9 December 2014; San Francisco, CA
   Google Scholar
• Komarova NL, Burger JA, Wodarz D. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA 2014;111(38):13906-11
   PubMed Web of Science ®Google Scholar
• Porcu P, Flinn I, Kahl BS, et al. Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-Kinase-δ,γ inhibitor, in patients previously treated with ibrutinib [abstract 3335]. AmericanSociety of Hematology (ASH) Annual Meeting; 6–9 December 2014; San Francisco, CA
   Google Scholar
• Roberts AW, Ma S, Brander DM, et al. Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) [abstract 325]. AmericanSociety of Hematology (ASH) Annual Meeting; 6–9 December 2014; San Francisco, CA
   Google Scholar
• Available from: www.mskcc.org/cancer-care/trial/14-215
   Google Scholar
• Salles GA, Boyd TE, Morschhauser F, et al. Preliminary results of a phase 1b study (GO28440) combining GDC–0199 (ABT–199) with bendamustine/rituximab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia [abstract 3337]. AmericanSociety of Hematology (ASH) Annual Meeting; 6–9 December 2014; San Francisco, CA
   Google Scholar
• Flinn I, Brunvand M, Dyer MJS, et al. Preliminary results of a phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia [abstract 4687]. AmericanSociety of Hematology (ASH) Annual Meeting. 6–9 December 2014; San Francisco, CA
   Google Scholar